Your session is about to expire
← Back to Search
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter for Breast Cancer
Study Summary
This trial is testing a virus that may kill cancer cells without damaging normal cells in patients with squamous cell carcinoma of the head and neck or breast cancer that has spread to other parts of the body.
- Breast Cancer
- HER2 Positive
- Head and Neck Cancers
- Progesterone Receptor Positive
- No change needed.
- Head and Neck Squamous Cell Carcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 1 & 2 trial • 48 Patients • NCT00450814Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What medical conditions is Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter a viable treatment for?
"Ocular clouding is often remedied using Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter. This same treatment has been observed to alleviate the symptoms of senile cataract, abscesses, and wound site healing."
What is the total number of volunteers enrolled in this clinical experiment?
"Unfortunately, this clinical study is not presently enrolling any more patients. The trial was initially posted on April 1st 2013 and revised last February 3rd 2022. If you are still interested in participating in a medical research project, there are currently 5545 trials searching for individuals with the erbb2 gene mutation and 11 studies looking to recruit volunteers who have been infected with an Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter."
Has the U.S. Food and Drug Administration sanctioned utilization of Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter?
"As this is a Phase 1 trial, with limited evidence of efficacy and safety, our team at Power gave Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter a score of one."
Is enrollment still possible for this research initiative?
"At the moment, this clinical trial is not open for participant recruitment. Initially posted on April 1st 2013 and last updated February 3rd 2022, it does not currently have any openings. There are presently 5545 trials looking for patients suffering from erbb2 gene related issues that do require volunteers as well as 11 studies searching for participants with Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter needs."
Are there any precedents for the usage of Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter in a clinical trial?
"Currently, 11 research initiatives related to Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter are ongoing with one study in Phase 3. A majority of these trials is being conducted out of Rochester, Minnesota; however, there are 75 different sites across the world that are running similar studies."
Share this study with friends
Copy Link
Messenger